Review

Depression and pain dynamics in lumbar degenerative disk disease: A systematic review and meta-analysis

Indira Karibayeva¹, Yerzhan Kuanyshbekov², Malika Idayat³, Botagoz Turdaliyeva⁴, Shayakhmet Makhanbetkhan⁵

¹Department of Health Policy and Community Health, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, GA, USA; ²Department of Spinal Neurosurgery and Peripheral Nervous System Pathology, National center for Neurosurgery, Astana, Kazakhstan; ³Department of Medicine and Healthcare, Al-Farabi Kazakh National University, Almaty, Kazakhstan; ⁴Kazakh Scientific Center of Dermatology and Infectious Diseases of the Ministry of Health of the Republic of Kazakhstan, Almaty, Kazakhstan; ⁵Central City Hospital, Almaty, Kazakhstan.

Abstract. Background and aim: This study systematically reviews the literature on changes in depression and pain scores in patients with lumbar degenerative disc disease (LDDD) after treatment initiation. Methods: A comprehensive review of PubMed, Web of Science, Science Direct, Academic Search Complete, and Google Scholar was performed. Pooled prevalence estimates, subgroup analysis, sensitivity analysis, and publication bias assessments were performed. Results: We identified eight eligible studies with 634 LDDD patients. Our meta-analysis indicated a slight reduction in the mean Beck Depression Inventory scores from baseline (11.51) to three months post-treatment (9.18). Conversely, there was a significant decrease in the mean Visual Analogue Scale back pain scores from baseline (6.72) to three months post-treatment (2.62). This suggests that treatment for LDDD may reduce pain levels in the short term; however, its effect on depression is limited. Additionally, patients in the conservative treatment group exhibited higher rates of depression both at baseline (12.32) and at the 3-month follow-up (9.45) than those in the operative treatment group (11.23 at baseline and 8.57 at the 3-month follow-up). In terms of pain, patients in the conservative treatment group reported lower pain scores at baseline (6.14) but higher scores at the 3-month follow-up (3.53) than those in the operative treatment group (7.68 at baseline and 1.45 at the 3-month follow-up). Conclusions: Our findings underscore the need for integrated treatment approaches that address both depression and pain to improve the outcomes of patients with LDDD. Although pain reduction is achievable, the management of depression remains a challenge. (www.actabiomedica.it)

Key words: lumbar degenerative disk disease, depression, pain, prevalence, systematic review, meta-analysis

Introduction

Degenerative spinal diseases, often driven by prolonged static and excessive dynamic loads, physical inactivity, and unique anatomical features like spinepelvic imbalance, present considerable challenges to individuals' overall well-being (1). Lumbar degenerative disc disease (LDDD) is a common musculoskeletal disorder characterized by structural changes in lumbar intervertebral discs (2). These changes, including disc degeneration, herniation, and narrowing of the spinal canal are the most common causes of acute and chronic back pain, restricted mobility, and a decline in quality of life, especially in individuals over 40 (2). The prevalence of lumbar degenerative disc disease (LDDD) is shaped by several factors, including the patient's location, ethnicity, age, gender, and genetic background (3). LDDD ranked among the

top causes of disability, morbidity, and years lived with disability (4). Consequently, LDDD represents a major health concern, with a substantial socioeconomic burden (5, 6). Treatment for LDDD includes a variety of strategies, ranging from non-invasive treatments to more advanced surgical options (7). Some studies also suggest that modifiable factors, such as reducing elevated body mass index (BMI), controlling hypertension, managing dyslipidemia and diabetes mellitus, as well as quitting smoking, can decrease the risk of intervertebral disc degeneration and herniation (3). Despite these approaches, some individuals opt to forego treatment, highlighting the complex nature of this condition and the multitude of factors influencing treatment decisions and outcomes in those patients (8, 9). Notably, depression is a prevalent comorbidity in individuals with LDDD, surpassing the prevalence rates observed in the general population. Ajiboye and colleagues report that the prevalence of depression among symptomatic LDDD patients is 32% (10). This comorbidity significantly heightens pain perception and functional impairment, ultimately compromising treatment outcomes and leading to increased healthcare utilization (11).

Pain, both physical and psychological, constitutes a defining feature of LDDD (12). Chronic low back pain, radicular pain, and neuropathic pain contribute significantly to morbidity, diminishing the overall quality of life of affected individuals (12). Recent studies highlight the important role of the neuroimmune interface, particularly the neuroimmune communication between the peripheral and central nervous systems, in the development of chronic pain. Evidence suggests neuroimmune activation within the central nervous system in LDDD patients, even in the absence of systemic inflammation (13). Several cytokines are elevated in both cerebrospinal fluid and blood serum, with their levels correlating to back pain severity. The connection between depression and pain in LDDD is also deeply intertwined. Chronic pain can lead to or worsen depression, while depression can intensify pain perception by affecting central sensitization and disrupting neuroendocrine regulation (14). Understanding the dynamics of depression and pain in LDDD is crucial for tailoring effective patient care and treatment strategies. No meta-analysis has been conducted to investigate changes in depression and pain scores after treatment initiation in LDDD patients. Therefore, this study aimed to perform a systematic review and meta-analysis to explore the changes in depression and pain scores three months after treatment initiation, based on the Beck Depression Inventory (BDI) and Visual Analog Scale (VAS) back pain scores. We sought to shed light on the interplay between depression and pain in LDDD, providing valuable insights for clinical practice and enhancing patient outcomes (15, 16).

Materials and Methods

The study protocol was registered with the PROS-PERO International Prospective Register of Systematic Reviews (ID: CRD42024561303).

The PROSPERO database was searched to identify similar studies, and no similar studies were found. We conducted a subsequent search of five major electronic literature databases: PubMed, Web of Science, ScienceDirect, Academic Search Complete, and Google Scholar. The literature search for the specified sources was initiated on January 1, 2024, and completed on June 1, 2024. The search strategy included the following keywords: "depression" and "degenerative disk disease"; "depressive disorder" and "degenerative disk disease"; "depression" and "degenerative disk' in all fields. The full search strategy is shown in Supplementary Table 1 (Table S1).

Methodologically, literature screening and synthesis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The inclusion criteria:

- 1. Cohort and cross-sectional studies, and database analyses.
- 2. Studies that included patients with LDDD.
- Studies reporting specific outcomes, including mean scores on the Visual Analog Scale (VAS) for back pain and Beck Depression Inventory (BDI) scores at baseline and three months post-treatment.

Author, year	Country	Study design	Mean age of study group ± SD or age groups	Patient number	Outcome measures	Procedure type	Follow-up	Risk of bias
Falavigna, 2011 (19)	Brazil	prospective cohort	61.54 ± 9.78	52	VAS, BDI	Operative treatment	22 months	9,5
Misterska, 2013 (20)	Poland	prospectivestudy	43.47	90	BDI	Operative treatment	No	9
Engel-Yeger, 2016 (21)	Israel	a cross-sectional	46.96 ± 14.36	51	VAS, BDI	Conservative treatment	No	9,5
Jablonska, 2017 (22)	Poland	prospective cohort	42.7±10.99	188	VAS, BDI	Operative treatment	6 months	9,5
Comella, 2017 (23)	USA	open label study	51.5	15	VAS, BDI	Conservative treatment	12 months	10
Celenlioglu, 2018 (15)	Turkey	prospective cohort	44,8	100	VAS, BDI	Conservative treatment	3 months	9,5
Sacaklidir, 2021 (24)	Turkey	prospective, observational	42.0 ± 9.5	58	VAS, BDI	Conservative treatment	3 months	9,5
Wu, 2021 (11)	China	retrospective trial	59.5 +-9.76	80	VAS, BDI	Operative treatment	24 months	9

Table 1. Summary of Included Articles Sorted by the Year of Publication.

Abbreviations: BDI - Beck Depression Inventory; SD - standard deviation; VAS - Visual Analogue Scale.

- 4. Studies published in English between January 2010 and March 2024.
- 5. Articles focusing on surgical interventions and conservative treatments.

The exclusion criteria:

- 1. Publications lacking essential information.
- 2. Studies duplicating previously reported findings.
- 3. Review articles or case reports involving fewer than ten patients.

In accordance with the PRISMA guidelines, two of the authors independently extracted the following information from the identified full-text articles using a standard data extraction form: (1) the first author's name, (2) publication year, (3) country, (4) study design, (5) sample size, (6) lesion location, (7) mean age, (8) mean ± SD BDI score pretreatment, (9) mean ± SD VAS back pain score pretreatment, (10) mean ± SD BDI score at 3-month follow-up, and (11) mean ± SD VAS back pain score at the 3-month follow-up. Any disagreements or conflicts were resolved by discussion and consensus.

Risk of bias

The Critical Appraisal Skills Programme (CASP) qualitative research checklist was employed to evaluate the methodological quality of the included studies (17). This checklist comprised ten questions covering various aspects, such as the study's objectives, methodology, research design, recruitment approach, data collection methods, researcher-participant relationships, ethical considerations, data analysis, research findings, and overall value. Each criterion was assessed with a rating of 'yes' when adequately described (scored as 1), 'no' when absent (scored as 0), and ' cannot tell' when unclear or incomplete (scored as 0.5). The total scores ranged from 0 to 10, with a score of at least 7 considered indicative of a satisfactory quality.

Statistical analysis

RStudio was used to calculate the pooled mean with 95% confidence intervals. We used a random effects model for the meta-analysis. We examined the following outcomes: BDI at baseline and 3 months and VAS Back Pain at baseline and 3 months. Forest plots were used to display pooled estimates using the "RevMan5" layout function. Heterogeneity across studies was assessed using subgroup analysis for treatment type and meta-regression analysis for year of publication. Influence diagnostics analysis was performed by identifying an outlier study whose confidence interval did not overlap with the confidence interval of the pooled effect. Publication bias was evaluated through visual inspection of a funnel plot and statistical analysis using Egger's test to examine potential asymmetry in the distribution of the study results.

Results

Description of the included studies

The initial database search yielded a total of 940 results. After removing 471 duplicates and 191 ineligible studies, 278 titles were screened for eligibility. Eight articles were included in the meta-analysis, based on the inclusion and exclusion criteria, 8 articles were included in the meta-analysis. A flowchart of the study selection is presented in Figure 1 (18).





Figure 1. PRISMA flow chart of study selection (18). Abbreviations: ACS: Academic Search Complete; DDD: Degenerative Disk Disease.

The study design and patient characteristics are presented in Table 1. All the included studies were published between 2011 and 2021. Geographically, the studies originated in diverse regions: three from South Asia, one from Latin America, two from Eastern Europe, one from North America, and one from East Asia. Among these studies, six were prospective, one was retrospective, and one was cross-sectional.

A total of 634 patients with LDDD were included in eight studies. The mean sample size was 79.25 patients, ranging from 15 to 188 patients per study. The mean age ranged from 42.0 to 59.5 years. The mean follow-up period ranged from 3 months to 2 years (Table 1).

Risk of bias (quality) assessment

All included studies had a CASP score of 9 or above, indicating high quality and a low risk of bias, as presented in Table 2.

Depression at baseline

Eight studies with ten groups presented the BDI scores at baseline. Based on the random-effects model, the pooled average mean of eight studies with ten groups on the BDI score at baseline in patients with LDDD was 11.51,95% CI [9.31;13.71], as presented in Figure 2. The test for heterogeneity suggested the presence of high heterogeneity: I^2 =88%, Q (df = 9) = 72.40, p < 0.01.

Subgroup analysis based on the type of treatment was conducted to investigate the sources of heterogeneity among the studies. Using the random-effects model, the pooled average mean BDI score for the five groups in the conservative treatment subgroup indicated high heterogeneity, with a score of 12.32 (95% CI [6.93; 17.71]), I² = 93%, Q (df = 4) = 59.61, p < 0.01. In contrast, the operative treatment subgroup exhibited moderate heterogeneity with a pooled mean BDI score of 11.23 (95% CI [9.72; 12.75]), I² = 46%, Q (df = 4) = 7.43, p = 0.11, as shown in Figure 3.

Meta-regression analysis by year of publication revealed significant changes in the effect sizes over time (Figure S1). The analysis demonstrated that year of publication is a significant moderator, with newer studies showing higher effect sizes than older ones. The influence analysis assessed the robustness of the pooled estimates. The diagnostic evaluation of BDI scores at baseline did not reveal any influential studies (Figure S2). Upon visual inspection of the funnel plot, no asymmetry was evident (Figure S3), which was confirmed by non-significant Egger's test (p= 0.3767).

Table 2. The Critical Appraisal Skills Programme (CASP) Qualitative Research Checklist.

Authors	Aim	Methodology	Design	Recruitment	Data collection	Relationship	Ethical	Data analysis	Finding	Values	Score
Celenhoglu, 2018 (15)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes	9,5
Engel-Yeger, 2016 (21)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes	9,5
Falavigna, 2011 (19)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes	9,5
Jablonska, 2017 (22)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes	9,5
Comella, 2017 (23)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	10
Misterska, 2013 (20)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Can't tell	Can't tell	Yes	9
Sacaklidir, 2021 (24)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes	9,5
Wu, 2021 (11)	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes	Yes	Can't tell	Yes	9

					Mean			Mea	n		
Study	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Ra	ndom	ı, 95	% C	I
Engel-Yeger, 2016	7.21	4.73	51	11.2%	7.21 [5.91; 8.51]		-				
Falavigna, 2011 (a)	8.57	4.92	13	9.5%	8.57 [5.90; 11.24]		-	_			
Kristin, 2017	9.05	6.82	15	8.5%	9.05 [5.60; 12.50]		-	—			
Falavigna, 2011 (b)	10.36	8.51	39	9.6%	10.36 [7.69; 13.03]						
Wu, 2021	11.00	7.00	80	11.0%	11.00 [9.47; 12.53]		-	+			
Misterska, 2013	11.86	7.23	90	11.0%	11.86 [10.37; 13.35]		-	-	-		
Jabłońska, 2017	12.10	6.74	188	11.5%	12.10 [11.14; 13.06]						
Sacaklidir, 2021	12.50	10.00	58	9.7%	12.50 [9.93; 15.07]			-			
Celenlioglu, 2018 (b)	16.40	13.10	61	8.7%	16.40 [13.11; 19.69]					- 1	
Celenlioglu, 2018 (a)	16.90	8.90	39	9.4%	16.90 [14.11; 19.69]					-	
Total (95% CI)			634	100.0%	11.51 [9.31; 13.71]			<u> </u>	-		
Heterogeneity: Tau ² = 7	.7028;	Chi ² = 7	72.40, o	lf = 9 (P ≤	< 0.01); I ² = 88%	I	1 1	1	I	I	I
						6	8 10	12	14	16	18

Figure 2. Pooled Baseline BDI Scores in Patients with LDDD.

Abbreviations: BDI: Beck Depression Inventory; C.I.: confidence interval; LDDD: lumbar Degenerative Disk Disease; SD: standard deviation.



Figure 3. Subgroup Analysis of the BDI Score at Baseline in Patients with LDDD by Treatment Type. Abbreviations: BDI: Beck Depression Inventory; C.I.: confidence interval; LDDD: lumbar Degenerative Disk Disease; SD: standard deviation.

Study	Mean	SD	Total	Weight	Mean IV, Random, 95% Cl	IV	/, Ra	Mea ndon	in 1, 959	% CI	
Sacaklidir, 2021	4.10	3.70	58	12.0%	4.10 [3.15; 5.05]	+					
Wu, 2021	5.20	2.80	80	12.6%	5.20 [4.59; 5.81]						
Kristin, 2017	5.60	1.88	15	12.0%	5.60 [4.65; 6.55]			1	-		
Engel-Yeger, 2016	6.02	2.21	51	12.6%	6.02 [5.41; 6.63]			- 1	-		
Celenlioglu, 2018 (a)	7.10	2.30	39	12.4%	7.10 [6.38; 7.82]			-			
Celenlioglu, 2018 (b)	7.70	2.00	61	12.7%	7.70 [7.20; 8.20]						
Falavigna, 2011 (b)	8.79	0.65	39	12.9%	8.79 [8.59; 8.99]						
Falavigna, 2011 (a)	9.00	0.70	13	12.8%	9.00 [8.62; 9.38]						
Total (95% CI)			356	100.0%	6.72 [5.26; 8.19]			_			
Heterogeneity: $Tau^2 = 2$	2.9601;	Chi ² =	300.42	2. df = 7 ($P < 0.01$); $I^2 = 98\%$			1			1
J	,			,	,,	4	5	6	7	8	9

Figure 4. Pooled Baseline VAS Back Pain Scores in Patients with LDDD.

Abbreviations: C.I.: confidence interval; LDDD: Lumbar Degenerative Disk Disease; SD: standard deviation; VAS: Visual Analogue Scale.

Pain at baseline

Six studies with eight groups presented the VAS back pain scores at baseline. Using the random-effects model, the pooled mean VAS back pain score at baseline for patients with LDDD was 6.72 (95% CI [5.26, 8.19]) (Figure 4). The test for heterogeneity indicated a high level of heterogeneity, $I^2 = 98\%$, Q (df = 7) = 300.42, p < 0.01.

Subgroup analysis based on the type of treatment revealed significant heterogeneity among the studies. Using the random-effects model, the pooled mean VAS score for the four groups in the conservative treatment subgroup was lower than that in the operative subgroup. Both subgroups exhibited high heterogeneity, with scores of 6.14 (95% CI [4.41; 7.87]), $I^2 = 98\%$, Q (df = 5) = 9.71, p < 0.01, and 7.68 (95% CI [2.39; 12.97]), $I^2 = 98\%$, Q (df = 2) = 125.2, p < 0.01, respectively, as shown in Figure 5.

Meta-regression analysis by year of publication revealed significant changes in effect sizes over time, as depicted in Figure S4. Studies published in earlier years have reported larger effect sizes than those reported in more recent studies. Sensitivity analysis was used to assess the robustness of the pooled estimates. The influence diagnostics of the VAS Back Pain Score at baseline did not reveal any influential studies (Figure S5). Upon visual inspection of the baseline VAS back pain funnel plot, asymmetry was evident, suggesting a non-symmetric distribution of the study results around the estimated effect size (Figure S6), which was confirmed by a significant Egger's test (p=0.001).

Depression at a 3-month follow up

Six studies with eight groups presented the dynamics of BDI scores at the 3 month follow up. Utilizing the random-effects model, the pooled average mean of these six studies, comprising eight groups, revealed a BDI score of 9.18 (95% CI [7.73; 10.64]) among patients with LDDD (Figure 6). A test for heterogeneity indicated significant heterogeneity $(I^2 = 54\%, Q (df = 7) = 15.36, p = 0.03).$

Subgroup analysis based on the type of treatment revealed significant variability among studies. Using the random-effects model, the pooled average mean BDI score for the four groups in the conservative treatment subgroup was higher than that in the operative subgroup, with scores of 9.45 (95% CI [5.94; 12.96]), I² = 69%, Q (df = 3) = 9.71, p = 0.02, and 8.57 (85% CI [7.31; 9.83]), I² = 18%, Q (df = 3) = 3.64, p = 0.02, respectively (Figure 7). Notably, heterogeneity within the operative treatment group was low.

Meta-regression analysis of the BDI score dynamics at 3 months by year of publication revealed significant changes in effect sizes over time, as depicted in Figure S7. Studies published in earlier years have reported larger effect sizes than those reported in more recent studies.

Study or					Mean	1		_ N	lean		
Subgroup	Mean	SD	Total	Weight	IV, Random,	95% CI	IV,	, Ranc	iom, 9	95% C	
treatment = conserv	vative										
Sacaklidir, 2021	4.10	3.70	58	12.0%	4.10 [3.15;	5.05]		-			
Kristin, 2017	5.60	1.88	15	12.0%	5.60 [4.65;	6.55]	_				
Engel-Yeger, 2016	6.02	2.21	51	12.6%	6.02 [5.41;	6.63]					
Celenlioglu, 2018 (a)	7.10	2.30	39	12.4%	7.10 [6.38;	7.82]		-	+		
Celenlioglu, 2018 (b)	7.70	2.00	61	12.7%	7.70 [7.20;	8.20]					
Total (95% CI)			224	61.7%	6.14 [4.41;	7.87]	-				
Heterogeneity: $Tau^2 = 1$	1.7750;	Chi ² =	54.53,	df = 4 (P	< 0.01); $I^2 = 93$	3%					
treatment = operativ	ve										
Wu, 2021	5.20	2.80	80	12.6%	5.20 [4.59;	5.81]	-	+			
Falavigna, 2011 (b)	8.79	0.65	39	12.9%	8.79 [8.59;	8.99]			+	-	
Falavigna, 2011 (a)	9.00	0.70	13	12.8%	9.00 [8.62;	9.38]			+	+	
Total (95% CI)			132	38.3%	7.68 [2.39;	12.97]					_
Heterogeneity: $Tau^2 = 4$	1.4625;	Chi ² =	= 12 5.2,	df = 2 (P	< 0.01); $I^2 = 98$	8%					
Total (95% CI)			356	100.0%	6.72 [5.26;	8.19]					
Heterogeneity: Tau ² = 2	2.9601;	Chi ² =	300.42	2, df = 7 (P < 0.01); I ² = 9	98%	I	I	I	I	I
Test for subgroup differ	ences:	Chi ² =	= 1.24, (df = 1 (P =	= 0.27)		4	6	8	10	12

Figure 5. Subgroup Analysis of the VAS Back Pain Score at Baseline in Patients with LDDD by Treatment Type Abbreviations: C.I.: confidence interval; LDDD: Lumbar Degenerative Disk Disease; SD: standard deviation; VAS: Visual Analogue Scale.

Study	Mean	SD	Total	Weight	Mean IV, Random, 95% C	I	IV, Ran	Mean dom, 95	% CI
Sacaklidir, 2021	7.90	9.00	58	12.7%	7.90 [5.58; 10.22]				
Kristin, 2017	8.20	8.20	15	5.9%	8.20 [4.05; 12.35]				
Jabłońska, 2017	8.30	5.69	188	23.6%	8.30 [7.49; 9.11]				
Falavigna, 2011 (b)	8.70	8.73	39	10.5%	8.70 [5.96; 11.44]	-	-		
Celenlioglu, 2018 (b)	8.70	8.40	61	14.0%	8.70 [6.59; 10.81]				
Wu, 2021	9.20	6.90	80	18.2%	9.20 7.69; 10.71		- i		
Celenlioglu, 2018 (a)	12.50	7.10	39	13.3%	12.50 [10.27; 14.73]			•	
Falavigna, 2011 (a)	15.53	15.74	13	1.7%	15.53 [6.97; 24.09]			•	
Total (95% CI)			493	100.0%	9.18 [7.73; 10.64]		•		
Heterogeneity: Tau ² = 1	.2632;	Chi ² = 1	15.36, d	lf = 7 (P =	= 0.03); I ² = 54%		I	I	I
				-		5	10	15	20

Figure 6. Pooled BDI Scores in Patients with LDDD at a 3-month Follow-up. Abbreviations: BDI: Beck Depression Inventory; C.I.: confidence interval; LDDD: lumbar Degenerative Disk Disease; SD: standard deviation.

Sensitivity analysis was used to assess the robustness of the pooled estimates. The influence diagnostics of the BDI score dynamics at three 3-months revealed that Celenlioglu, 2018 (15) (study #7) was an outlier (pooled average mean BDI score = 12.50, 95% CI [10.27; 14.73]),

as shown in Figure S8. A visual inspection of the funnel plot for BDI score dynamics at 3 months suggested a symmetric distribution of study results around the estimated effect size, which was confirmed by nonsignificant Egger's test p = 0.2397 (Figure S9).

Study or Subgroup	Mean	SD	Total	Weight	Mean IV, Random,	95% CI	IV,	Mean Random, s	95% CI
treatment = conserv	vative								
Sacaklidir, 2021	7.90	9.00	58	12.7%	7.90 [5.58;	10.22]		_	
Kristin, 2017	8.20	8.20	15	5.9%	8.20 [4.05;	12.35]			
Celenlioglu, 2018 (b)	8.70	8.40	61	14.0%	8.70 [6.59;	10.81]			
Celenlioglu, 2018 (a)	12.50	7.10	39	13.3%	12.50 [10.27	; 14.73]			
Total (95% CI)			173	45.9%	9.45 [5.94;	12.96]			
Heterogeneity: $Tau^2 = 3$	8.4835; (Chi ² = 9	9.7 <mark>1</mark> , df	= 3 (P =	0.02); I ² = 69%)			
treatment = operativ	ve								
Jabłońska, 2017	8.30	5.69	188	23.6%	8.30 [7.49;	9.11]	+		
Falavigna, 2011 (b)	8.70	8.73	39	10.5%	8.70 [5.96;	11.44]			
Wu, 2021	9.20	6.90	80	18.2%	9.20 [7.69;	10.71]			
Falavigna, 2011 (a)	15.53	15.74	13	1.7%	15.53 [6.97;	24.09]			
Total (95% CI)			320	54.1%	8.57 [7.31;	9.83]	•	•	
Heterogeneity: $Tau^2 = 0$	0.0098; (Chi ² = 3	3.64, df	= 3 (P =	0.30); I ² = 18%)			
Total (95% CI)			493	100.0%	9.18 [7.73;	10.64]	_		
Heterogeneity: Tau ² = 1	1.2632; (Chi ² = '	15.36, d	lf = 7 (P =	= 0.03); I ² = 549	%	I		
Test for subgroup differ	ences: (Chi ² = (0.57, df	= 1 (P =	0.45)		5	10 15	20

Figure 7. Subgroup Analysis of BDI Score Dynamics at a 3-Month Follow-Up in Patients with LDDD by Treatment Type.

Abbreviations: BDI: Beck Depression Inventory; C.I.: confidence interval; LDDD: lumbar Degenerative Disk Disease; SD: standard deviation.

Study	Mean	SD	Total	Weight	Mean IV, Random, 95% Cl	Mean IV, Random, 95% Cl
Wu, 2021	0.50	1.50	80	15.0%	0.50 [0.17; 0.83]	-
Sacaklidir, 2021	1.40	2.50	58	14.6%	1.40 [0.76; 2.04]	— <mark>—</mark> —
Falavigna, 2011 (b)	1.67	1.22	39	15.0%	1.67 [1.29; 2.05]	
Falavigna, 2011 (a)	2.31	1.43	13	14.3%	2.31 [1.53; 3.09]	— <u> </u>
Celenlioglu, 2018 (b)	3.30	2.80	61	14.5%	3.30 [2.60; 4.00]	
Kristin, 2017	4.20	2.67	15	12.9%	4.20 [2.85; 5.55]	
Celenlioglu, 2018 (a)	5.40	3.30	39	13.7%	5.40 [4.36; 6.44]	
Total (95% CI)			305	100.0%	2.62 [1.05; 4.20]	
Heterogeneity: $Tau^2 = 2$	2.7122;	Chi ² =	135.09	9, df = 6 ($P < 0.01$; $I^2 = 96\%$	
<u> </u>						1 2 3 4 5 6

Figure 8. Pooled VAS Back Pain Scores in Patients with LDDD at a 3-month Follow-up. Abbreviations: C.I.: confidence interval; LDDD: Lumbar Degenerative Disk Disease; VAS: Visual Analogue Scale

Pain at 3-month follow-up

Five studies with seven groups presented the VAS Back Pain score dynamics at the 3-month follow-up. Based on the random-effects model, the pooled average mean VAS back pain score at 3 months in patients with LDDD was 2.62 (95% CI [1.05; 4.20]). A test for

heterogeneity indicated a high level of heterogeneity (I² = 96%, Q (df = 6) = 135.09, p < 0.01), as shown in Figure 8.

Subgroup analysis based on the type of treatment revealed significant heterogeneity among the studies. Utilizing the random-effects model, the pooled average VAS back pain score at the 3-month follow-up

Study or Subgroup	Mean	SD	Total	Weight	Mean IV, Random, 95% Cl	I	V, Rar	Mean Idom,	95%	СІ	
treatment = conser	vative										
Sacaklidir, 2021	1.40	2.50	58	14.6%	1.40 [0.76; 2.04]			-			
Celenlioglu, 2018 (b)	3.30	2.80	61	14.5%	3.30 [2.60; 4.00]				_		
Kristin, 2017	4.20	2.67	15	12.9%	4.20 [2.85; 5.55]			—			-
Celenlioglu, 2018 (a)	5.40	3.30	39	13.7%	5.40 [4.36; 6.44]				-	-	
Total (95% CI)			173	55.7%	3.53 [0.82; 6.23]						
Heterogeneity: Tau ² = 2	2.7032;	Chi ² =	48.03,	df = 3 (P	< 0.01); I ² = 94%						
treatment = operati	ve					_					
Wu, 2021	0.50	1.50	80	15.0%	0.50 [0.17; 0.83]		-				
Falavigna, 2011 (b)	1.67	1.22	39	15.0%	1.67 [1.29; 2.05]						
Falavigna, 2011 (a)	2.31	1.43	13	14.3%	2.31 [1.53; 3.09]						
Total (95% CI)			132	44.3%	1.45 [-0.82; 3.72]				-		
Heterogeneity: Tau ² = 0	0.7621;	Chi ² =	30.6, (df = 2 (P -	< 0.01); I ² = 93%						
Total (95% CI)		0	305	100.0%	2.62 [1.05; 4.20]	_					_
Heterogeneity: Tau ² = 2	2.7122;	Chi ² =	: 135.09	9, df = 6 (P < 0.01); I ^z = 96%	I	1 1		I	I	1
Test for subaroup diffe	rences:	Chi ² =	: 4.31. (df = 1 (P =	= 0.04)	0	1 2	2 3	4	5	6

Figure 9. Subgroup Analysis of VAS Back Pain Score Dynamics at a 3-Month Follow-Up in Patients with LDDD by Treatment Type.

Abbreviations: C.I.: confidence interval; LDDD: Lumbar Degenerative Disk Disease; SD: standard deviation; VAS: Visual Analogue Scale.

for the four groups in the conservative treatment subgroup was higher than that in the operative subgroup. The scores were 3.53 (95% CI [0.82; 6.23]), $I^2 = 94\%$, Q(df=3)=48.03, p<0.01, and 1.45(95% CI [-0.82; 3.72]), $I^2 = 93\%$, Q(df = 2) = 30.6, p < 0.01, respectively. Both groups exhibited high heterogeneity, as shown in Figure 9.

Meta-regression analysis of the VAS back pain score dynamics at a 3-month follow-up by year of publication did not reveal significant changes in effect sizes over time, as depicted in Figure S10. Sensitivity analysis was used to assess the robustness of the pooled estimates. The influence diagnostics of the VAS back pain score dynamics at the 3-month follow-up revealed that Kristin Comella, 2017 (23) (study #6) was an outlier (pooled average mean VAS back pain score = 4.20, 95% CI [2.85; 5.55]), as shown in Figure S11. A visual inspection of the funnel plot for VAS back pain score dynamics at 3 months suggested an asymmetric distribution of study results around the estimated effect size, which was confirmed by significant Egger's test (p = 0.0003) (Figure S12).

Discussion

This systematic review and meta-analysis aimed to explore how depression and pain change in patients with LDDD from baseline to three months after treatment. Our findings offer several important insights into the relationship between depression and pain in these patients, which carry significant clinical implications. Our meta-analysis, using a random-effects model, showed a modest decrease in the mean BDI scores from 11.51 at baseline to 9.18 at three months post-treatment. In contrast, we observed a substantial reduction in the mean VAS back pain scores, dropping from 6.72 at baseline to 2.62 after three months. This suggests that while treatment for LDDD may effectively lower pain levels in the short term, its impact on depression is less pronounced.

Additionally, our study found that patients receiving conservative treatment had higher depression rates both at baseline (12.32) and at the three-month follow-up (9.45) compared to those undergoing operative treatment, who had depression scores of 11.23 at baseline and 8.57 at follow-up. Regarding pain,

patients in the conservative treatment group reported lower pain scores at baseline (6.14) but higher scores at the three-month follow-up (3.53) compared to the operative treatment group, which had baseline scores of 7.68 and follow-up scores of 1.45. Our findings align with previous research that indicates a high prevalence of depression among patients with LDDD and underscores the bidirectional relationship between depression and pain. Studies have demonstrated that mental health-related quality of life significantly impacts the subjective experience of pain; specifically, the severity of depression correlates with the severity of pain and the clinical severity of lumbar disease (25-27). Moreover, a meta-analysis on the prognostic value of fear-avoidance beliefs in LDDD patients shows that high fear-avoidance beliefs predict less improvement in postoperative pain intensity and back-specific function, and this effect is sustained for more than 12 months after surgery (28). Our findings also align with existing research, emphasizing the psychological burden of chronic pain in conservative management (29).

In patients with LDDD, chronic pain and depression affect more than just quality of life and disability, impacting social and economic aspects as well, as evidenced by increased opioid use and greater utilization of healthcare resources (30). Research on opioid use in patients undergoing lumbar surgery for degenerative lumbar spine conditions reveals that preoperative and perioperative opioid intake, the presence of degenerative disc disease, multiple prescribers, and depression are significant predictors of prolonged and intensive opioid use post-surgery (31).

One limitation of our study was the high heterogeneity observed among the included studies, which may have affected the robustness of our findings. Additionally, the three-month follow-up period may be insufficient for capturing the long-term changes in depression and pain levels. Another meta-analysis conducted by the authors of the present analysis, which assesses longterm postoperative outcomes of minimally invasive transforaminal interbody fusion in spondylolisthesis patients, indicates that improvements in pain and functional disability tend to decline over time (32).

Future research should focus on investigating the long-term effects of LDDD treatment on depression and pain. Additionally, studies exploring the mechanisms underlying the relationship between depression and pain in patients with LDDD may provide valuable insights into novel treatment approaches.

In conclusion, this systematic review and metaanalysis provide valuable insights into the dynamics of depression and pain in patients with LDDD. Our findings underscore the need for integrated treatment approaches that address both depression and pain to improve the outcomes of patients with LDDD. Although pain reduction is achievable, the management of depression remains a challenge. Future research should explore multidisciplinary approaches and long-term outcomes to optimize patient care.

Author Contribution Statement: IK: Conceptualization, Methodology, Investigation, Formal Analysis, Visualization, Writing – original/draft preparation, Writing–Review and Editing. YK: Resources, Software, Data curation, Supervision, Writing – original/draft preparation, writing–review and editing. MI: Validation, Writing – Review, and Editing. BT: Writing – original/draft preparation, Supervision, Project Administration, Investigation. SM: Writing–Review and Editing, Project Administration.

Funding Statement: This research received no specific grant from any funding agency.

Availability of Data: The data used for the analysis in this study are available from the corresponding author upon reasonable request.

Study Registration: The study protocol was registered in the PROSPERO database (Reference: CRD42024561303).

Ethics Statement: The Ethics Commission of Kazakhstan Medical University "KSPH" approved this study under study number #IRB-164-2024, dated 02.05.2024.

Conflict of Interest: The authors declare no conflict of interest regarding this article.

References

1. Fanuele JC, Birkmeyer NJO, Abdu WA, Tosteson TD, Weinstein JN. The Impact of Spinal Problems on the Health Status of Patients: Have We Underestimated the Effect? Spine. 2000 Jun;25(12):1509–14. doi: 10.1097/00007632 -200006150-00009.

- 2. Deane JA, McGregor AH. Current and future perspectives on lumbar degenerative disc disease: a UK survey exploring specialist multidisciplinary clinical opinion. BMJ Open. 2016 Sep;6(9):e011075. doi: 10.1136/bmjopen-2016-011075
- 3. Hoffeld K, Lenz M, Egenolf P, et al. Patient-related risk factors and lifestyle factors for lumbar degenerative disc disease: a systematic review. Neurochirurgie. 2023 Sep;69(5):101482. doi: 10.1016/j.neuchi.2023.101482
- 4. Palliyil NS, Shah S, Rai RR, Dalvie S, Monteiro J. Idade Deve ser levada em conta? Estudo da morbidade perioperatória e a evolução no longo prazo dos pacientes acima de 70 anos submetidos à cirurgia da coluna vertebral, devido a doenças degenerativas lombares. Rev Bras Ortop. 2020 Jun;55(03):298–303. doi: 10.1055/s-0039-1700833
- Zhao L, Manchikanti L, Kaye AD, Abd-Elsayed A. Treatment of Discogenic Low Back Pain: Current Treatment Strategies and Future Options—a Literature Review. Curr Pain Headache Rep. 2019 Nov;23(11):86-96. doi: 10.1007 /s11916-019-0821-x
- Kirnaz S, Capadona C, Wong T, et al. Fundamentals of Intervertebral Disc Degeneration. World Neurosurg. 2022 Jan;157:264–73. doi: 10.1016/j.wneu.2021.09.066
- Ajiboye LO, Alimi M, Gbadegesin SA, Oboirien M. Treatment outcome of quality of life and clinical symptoms in patients with symptomatic lumbar degenerative disc diseases: which treatment modality is superior? Int Orthop. 2019 Apr;43(4):875-881. doi: 10.1007/s00264-018-4248-5.
- Bydon M, Alvi MA, Goyal A. Degenerative Lumbar Spondylolisthesis. Neurosurg Clin N Am. 2019 Jul;30(3): 299–304. doi: 10.1016/j.nec.2019.02.003
- 9. Vanti C, Ferrari S, Guccione AA, Pillastrini P. Lumbar spondylolisthesis: STATE of the art on assessment and conservative treatment. Arch Physiother. 2021 Dec;11(1): 19-29. doi: 10.1186/s40945-021-00113-2
- Ajiboye LO, Oboirien M. The Incidence and Association of Mental Depression with Symptomatic Lumbar Degenerative Disc Disease and Treatment Outcome. Health (N Y). 2018;10(11):1487–97. doi: 10.4236/health.2018.1011114
- 11. Wu B, Tian X, Shi C, et al. Clinical Outcomes of "U" Route Transforaminal Percutaneous Endoscopic Lumbar Discectomy in Chronic Pain Patients with Lumbar Spinal Stenosis Combined with Disc Herniation. Valença MM, editor. Pain Res Manag. 2021 Jan 19;2021:1–9. doi: 10.1155/2021/6657463
- 12. De Schepper EIT, Damen J, Van Meurs JBJ, et al. The Association Between Lumbar Disc Degeneration and Low Back Pain: The Influence of Age, Gender, and Individual Radiographic Features. Spine. 2010 Mar;35(5):531–36. doi: 10.1097/brs.0b013e3181aa5b33
- Rosenström AHC, Ahmed AS, Kultima K, et al. Unraveling the neuroimmune interface in chronic pain—the association between cytokines in the cerebrospinal fluid and pain in patients with lumbar disk herniation or degenerative disk disease. Pain. 2024 Feb;165(7):e65-e79. doi: 10.1097 /j.pain.000000000003175

- Borenstein DG, Balagué F. Low Back Pain in Adolescent and Geriatric Populations. Rheum Dis Clin N Am. 2021 May;47(2):149–63. doi: 10.1016/j.rdc.2020.12.001
- Celenlioglu AE, Sencan S, Gunduz OH. Does facet tropism negatively affect the response to transforaminal epidural steroid injections? A prospective clinical study. Skeletal Radiol. 2019 Jul;48(7):1051–58. doi:10.1007/s00256-018 -3129-8
- 16. Hayden JA, Ellis J, Ogilvie R, et al. Some types of exercise are more effective than others in people with chronic low back pain: a network meta-analysis. J Physiother. 2021 Oct;67(4):252–62. doi: 10.1016/j.jphys.2021.09.004
- CASP. CASP. CASP Qualitative Research Checklist, 2017. Critical Appraisal Skills Programme, UK (2017) https:// casp-uk.net/casp-tools-checklists/ [Accessed May 20, 2024].
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;n71. doi: 10.1136/bmj.n71
- Falavigna A, Righesso O, Traynelis VC, Teles AR, Silva PGD. Effect of deep wound infection following lumbar arthrodesis for degenerative disc disease on long-term outcome: a prospective study: Clinical article. J Neurosurg Spine. 2011 Oct;15(4):399–403. doi: 10.3171/2011.5.spine10825
- 20. Głowacki M. Chronic pain coping styles in patients with herniated lumbar discs and coexisting spondylotic changes treated surgically: Considering clinical pain characteristics, degenerative changes, disability, mood disturbances, and beliefs about pain control. Med Sci Monit. 2013;19:1211–20. doi: 10.12659/msm.889729
- 21. Engel-Yeger B, Keren A, Berkovich Y, Sarfaty E, Merom L. The role of physical status versus mental status in predicting the quality of life of patients with lumbar disk herniation. Disabil Rehabil. 2018 Jan 30;40(3):302–8. doi: 10.1080 /09638288.2016.1253114
- 22. Jabłońska R, Ślusarz R, Królikowska A, Haor B, Antczak A, Szewczyk M. Depression, social factors, and pain perception before and after surgery for lumbar and cervical degenerative vertebral disc disease. J Pain Res. 2017 Jan;Volume 10:89–99. doi: 10.2147/jpr.s121328
- Comella K, Silbert R, Parlo M. Effects of the intradiscal implantation of stromal vascular fraction plus platelet rich plasma in patients with degenerative disc disease. J Transl Med. 2017 Dec;15(1):12-20. doi: 10.1186/s12967 -016-1109-0
- 24. Sacaklidir G, Sencan S, Sacaklidir R, Gunduz OH. The effect of spinopelvic parameters on transforaminal epidural steroid injection treatment success in lumbar disc herniation. Int J Clin Pract. 2021 Nov;75(11). doi: 10.1111/ijcp.14708
- 25. Kao YC, Chen JY, Chen HH, Liao KW, Huang SS. The association between depression and chronic lower back pain from disc degeneration and herniation of the lumbar spine. Int J Psychiatry Med. 2022 Mar;57(2):165–77. doi: 10.1177/00912174211003760
- 26. Tetsunaga T, Misawa H, Tanaka M, et al. The clinical manifestations of lumbar disease are correlated with self-rating

depression scale scores. J Orthop Sci. 2013 May;18(3): 374–79. doi: 10.1007/s00776-013-0363-8

- Stienen MN, Smoll NR, Joswig H, et al. Influence of the mental health status on a new measure of objective functional impairment in lumbar degenerative disc disease. Spine J. 2017 Jun;17(6):807–13. doi: 10.1016/j.spinee.2016.12.004
- 28. Zhao Z, Li J, Zhang R, Feng Y, He Y, Sun Z. The prognostic value of fear-avoidance beliefs on postoperative pain and dysfunction for lumbar degenerative disk disease: a meta-analysis. Int J Rehabil Res. 2023 Mar;46(1):3–13. doi: 10.1097/mrr.000000000000567
- TurkDC, Swanson KS, Tunks ER. Psychological Approaches in the Treatment of Chronic Pain Patients—When Pills, Scalpels, and Needles are Not Enough. Can J Psychiatry. 2008 Apr;53(4):213–23. doi: 10.1177/070674370805300402
- 30. Upfill-Brown A, Policht J, Sperry BP, et al. National trends in the utilization of lumbar disc replacement for lumbar degenerative disc disease over a 10-year period, 2010 to 2019. J Spine Surg. 2022 Sep;8(3):343–52. doi: 10.21037 /jss-22-4
- 31. Reitman CA, Ward R, Taber DJ, et al. Opioid Use Patterns in a Statewide Adult Medicaid Population Undergoing

Elective Lumbar Spine Surgery. Spine. 2022 Oct;48(3): 203-213. doi: 10.1097/brs.00000000004503

32. Y.Kuanyshbekov, I.Karibayeva. Long Term Clinical Outcomes of Minimally Invasive Transforaminal Interbody Fusion (MIS-TLIF) for Lumbar Spondylolisthesis in a Geriatric Population: a Systematic Review and Meta-Analysis. https://www.crd.york.ac.uk/prospero/display_record.php? RecordID=538220.

Correspondence:

- Received: 12 August 2024
- Accepted: 24 September 2024
- Yerzhan Kuanyshbekov, MD
- Department of Spinal Neurosurgery and Peripheral Nervous System Pathology, National center for Neurosurgery, Astana,
- Kazakhstan, 010000
- E-mail: erjan_k96@mail.ru
- ORCID: 0009-0007-5142-833X.

ANNEX



Figure S1. Meta-Regression Analysis of the BDI Score at Baseline in Patients with LDDD by Year of Publication. Abbreviations: BDI: Beck Depression Inventory; LDDD: Lumbar Degenerative Disk Disease.



Figure S2. Influence Diagnostics for BDI Score at Baseline in Patients with LDDD. Abbreviations: BDI: Beck Depression Inventory; LDDD: Lumbar Degenerative Disk Disease.



Funnel Plot for Publication Bias

Figure S3. Publication Bias Assessment for the BDI Score at Baseline in Patients with LDDD. Abbreviations: BDI: Beck Depression Inventory; C.I.: confidence interval; LDDD: Lumbar Degenerative Disk Disease; SD: standard deviation.



Figure S4. Meta-Regression Analysis of the VAS Back Pain Score at Baseline in Patients with LDDD by Year of Publication.

Abbreviations: LDDD: Lumbar Degenerative Disk Disease; VAS: Visual Analogue Scale.



Figure S5. Influence Diagnostics for VAS Back Pain Score at Baseline in Patients with LDDD. Abbreviations: LDDD: Lumbar Degenerative Disk Disease; VAS: Visual Analogue Scale.



Figure S6. Publication Bias Assessment for the VAS Back Pain Score at Baseline in Patients with LDDD. Abbreviations: LDDD: Lumbar Degenerative Disk Disease; VAS: Visual Analogue Scale.



Meta-Regression of 3months_BDI Scores by Year



Abbreviations: BDI: Beck Depression Inventory; LDDD: lumbar Degenerative Disk Disease.

Funnel Plot for Publication Bias



Figure S8. Influence Diagnostics for BDI Score Dynamics at a 3-Month Follow-up in Patients with LDDD. Abbreviations: BDI: Beck Depression Inventory; LDDD: Lumbar Degenerative Disk Disease.



Funnel Plot for Publication Bias

Figure S9. Publication Bias Assessment for the BDI Score Dynamics at a 3-Month Follow-up in Patients with LDDD.

Abbreviations: BDI: Beck Depression Inventory; LDDD: Lumbar Degenerative Disk Disease.



Meta-Regression of the VAS Back Pain Score at 3-Months by Year

Figure S10. Meta-Regression Analysis of the VAS Back Pain Score Dynamics at a 3-Month Follow-up in Patients with LDDD by Year of Publication.

Abbreviations: BDI: Beck Depression Inventory; LDDD: lumbar Degenerative Disk Disease.



Figure S11. Influence Diagnostics for VAS Back Pain Score Dynamics at a 3-Month Follow-up. Abbreviations: LDDD: Lumbar Degenerative Disk Disease; VAS: Visual Analogue Scale.



Funnel Plot for Publication Bias

Figure S12. Publication Bias Assessment for the Visual Analogue Scale Back Pain Score Dynamics at a 3-Month Follow-up.

			Academic Search	
Pubmed	Web of Science	Science Direct	complete	Google Scholar
Criteria: Search in	Criteria: Search in	Criteria: Search in	Criteria: Search in	Criteria: Search in
All Fields.	All Fields.	All Fields.	All Fields.	Abstract.
Filter: none	Filter: include only	Filter: include only	Filter: include only	Filter: Do not include
Search date:	"Articles"	Content type: Research	publications in	patents. Do not include
January - March 2024	Search date:	Articles. Search date:	English, and academic	citations. Exclude
1. Depression	January - March 2024	January - March 2024	journals. Search: Title/	review
degenerative disk	1. Depression	1. Depression AND	Abstract	Search date:
disease	degenerative disk	"degenerative disk"	Search date:	January - March 2024
2. Pain degenerative	2. Pain degenerative	2. Pain AND	January - March 2024	1. abstract: Depress*
disk disease	disk	degenerative disk:	Depression AND	"Degenerative disk"
(English only)		search in Title/	"degenerative disk"	-review -cancer
		abstract or Keywords.	Pain AND	-animal - 86
			"degenerative disk"	2. abstract: Pain AND
				"Degenerative disk"
				-cancer -animal
				-review -poster - 30

S1 Table. Search strategy of the Systematic Review of the depression and Pain Dynamics in Lumbar Degenerative Disk Disease in LDDD.